Anvive develops effective vaccine against Valley Fever in dogs

by Katie Pfaff

Pet health technology company, Anivive Lifesciences Inc., reports 100% protection based on results from its antifungal vaccine for canine Valley Fever. The study met its primary endpoint and found that the vaccine prevented clinical disease in dogs vaccinated.

"This study provides important data that validates our model and demonstrates the ability of the vaccine to afford protection against exposure to an extremely virulent fungal pathogen," said Anivive Chief Medical Officer David Bruyette, DVM, DACVIM. "To date, no vaccine exists to protect against systemic fungal disease, so this is an important step forward in our progress to develop a vaccine for Valley Fever and other fungal diseases in animals and humans."

The blinded, randomized, and placebo-controlled study included dogs given the study vaccine and tested with a fungus that causes a systemic disease called Valley Fever. The strain, Coccidioides, used in the study can cause the disease. Study canines were given a booster injection one month later.

Dogs were tested for fungal burden, radiographic changes, gross and histopathological lung lesions. Among the vaccinated groups, all measures were reduced, and dogs did not develop clinical disease. Some 30 million dogs are thought to be at risk for the disease based on the geographic location of fungal spores.

Source: https://www.prnewswire.com/news-releases/anivive-announces-positive-study-results-for-antifungal-vaccine-to-prevent-canine-valley-fever-301315181.html

Like1

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies